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ABSTRACT 
Non-celiac gluten sensitivity (NCGS), also referred to as non-celiac wheat sensitivity (NCWS), is a clinical syndrome characterized 
by both intestinal and extra-intestinal symptoms responsive to the withdrawal of gluten-containing food from the diet. The aim of this 
review is to summarize recent advances in research and provide a brief overview of the history of the condition for the benefit of 
professionals working in gastroenterology. Academic databases such as PubMed and Google Scholar were searched using key words 
such as ”non-celiac gluten sensitivity”, “gluten related disorders”, and the studies outlined in reference page were selected and 
analysed.  
 Most of the analysed studiers agree that NCGS would need to be diagnosed only after exclusion of celiac disease and wheat allergy, 
and that a reliable serological marker is not available presently. The mechanisms causing symptoms in NCGS after gluten ingestion 
are largely unknown, but recent advances have begun to offer novel insights. The estimated prevalence of NCGS, at present, varies 
between 0.6 and 6%. There is an overlap between irritable bowel syndrome and NCGS with regard to the similarity of gastrointestinal 
symptoms. The histologic characteristics of NCGS are still under investigation, ranging from normal histology to slight increase in 
the number of T lymphocytes in the superficial epithelium of villi. Positive response to gluten free diet for a limited period (e.g., 6 
weeks), followed by the reappearance of symptoms after gluten challenge appears, at this moment, to be the best approach for 
confirming diagnosis. The Salerno expert criteria may help to diagnose NCGS accurately in particular for research purposes but it has 
limited applicability in clinical practice. 
Keywords: Celiac disease, Non celiac gluten sensitivity, Wheat allergy. 
(Please cite as: Casella G, Villanacci V, Di Bella C, Bassotti G, Bold J, Rostami K. Non celiac gluten sensitivity and 
diagnostic challenges. Gastroenterol Hepatol Bed Bench 2018;11(3):197-202). 
 
Non Celiac Gluten Sensitivity  1  
Non-celiac gluten sensitivity (NCGS) is a clinical 
syndrome characterized by both intestinal and extra-
intestinal symptoms responsive to the withdrawal of 
wheat and related cereals from the diet (1). These 
symptoms have been found to relapse following a 
gluten challenge NCGS may be diagnosed only after 
exclusion of celiac disease (CD) and wheat allergy as 
an established serological marker is not yet available. 
NCGS is often suspected by the patients themselves 
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leading to self-diagnosis and self-treatment (2). It is 
important to consider that wheat, in addition to gliadin, 
contains a number of other potentially bioactive 
components that may cause gastrointestinal symptoms 
such as amylase trypsin inhibitors (ATIs) (3) and 
fermentable oligo-disaccharides-monosaccharides and 
polyols (FODMAPs) (4). A large number of IBS 
patients appear to respond to GFD, suggesting that 
gluten-containing food may be a trigger for IBS 
symptoms in at least a significant subset of patients (5).  
History of NCGS 
The concept of NCGS was described for the first time 
in 1978 by Ellis et al. (6).  These authors reported some 
patients with abdominal pain and diarrhea without 
histological duodenal lesions who improved after GFD. 
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Similarly, in 1980, Cooper et al. (7) reported 8 females 
with abdominal pain, diarrhea and normal duodenal 
histology who again improved with GFD, with 
reoccurrence of symptoms following gluten challenge. 
The consensus findings of the first international expert 
meeting where NCGS has been defined was published 
in 2012 (8).  
Composition of Wheat 
White Flour comprises about 80% starch and 10% 
protein (9). The indigestible oligosaccharides such as 
fructo-oligosaccharides and fructans constitute 13.4% 
of the dietary fiber in wheat (9) the latter contains also 
a considerable amount of indigestible ologisacharides 
galactans (9). Gluten represents 75-80% of the wheat 
proteins and it comprises 2 major groups: the glutenin 
and the gliadin proteins. Due to their amino acid 
sequences, the gluten proteins are partially resistant to 
digestion in the upper gastrointestinal tract, thus 
resulting in the formation of various peptides with a 
high degree of potential immunogenicity in the small 
intestine (10).  
Pathophysiology of NCGS 
The mechanisms that determine symptoms in NCGS 
after gluten ingestion are still largely unknown, but it is 
evident that there are marked differences with CD, a 
condition that is related to an autoimmune process with 
adaptive immune system activation, as well as wheat 
allergy (WA), which is IgE-dependent (1). Sapone et 
al. (8) (6) suggests that intestinal permeability and 
adaptive immune system may have a less pronounced 
role in NCGS than in CD. Having said that, the 
presentation of NCGS is not yet fully understood and 
this issue is controversial as we explain below.  
It is worth noting that gluten has been found to have 
some intrinsic biologic properties (11) causing 
alteration of cellular morphology and motility (12), as 
well as cytoskeleton organization and intercellular 
contact through the tight junction proteins (13).  
Some Gliadin peptides bind the TLR2 receptor that 
increase Interleukin 1 production, a proinflammatory 
cytokine, through the mediation of Myd88 (14). 
MyD88 is a key protein mediating the release of 
zonulin in response to gluten ingestion and this 
increases the mucosal permeability. NCGS patients 
show higher levels of TLR2 compared to those with 
CD, causing dysbiosis similar to that observed in the 
pathogenesis of inflammatory bowel disease (IBD) 
(15).  
The intestinal cells exposed to gluten show a reduced 
survival, as suggested by increased apoptosis and a 
reduction of nucleic acid (DNA and RNA) and protein 
synthesis (16). 
A study by Junker et al. (3) pointed the attention 
toward other molecules in wheat, the ATIs, capable of 
triggering the Toll-like receptor 4 pathways leading to 
the release of proinflammatory cytokines (3).  
In addition, non-protein components of wheat, the 
fermentable oligo-disaccharides-monosaccharides and 
polyols (FODMAPs), have been found to cause non-
specific gastrointestinal symptoms in the context of 
NCGS (1).  
In 2016, Uhde, et al. (17) showed that individuals with 
wheat sensitivity display highly increased serum levels 
of intestinal fatty acid-binding protein, in conjunction 
with elevated levels of soluble CD14, lipopolysacchide 
(LPS)-binding protein, and antibodies to bacterial LPS 
and flagellin, all of which declined in response to the 
elimination of gluten-containing food (i.e., wheat, rye, 
and barley) from diet. The study provided clear 
evidence for an immunological mechanism underlying 
NCGS distinct from CD, whereby intestinal epithelial 
cell damage leads to microbial tranalsocation and 
extensive systemic immune activation. The study also 
provided a panel of objective serologic markers with 
diagnostic potential. Because circulating microbial LPS 
is known to bind directly to TLR4 on the luminal 
surface of brain blood vessels with increased local 
cytokine secretion (18), the findings may also explain 
some of the neuropsychiatric symptoms related to 
NCGS.   
Genetic of NCGS 
 Up to half of NCGS patients may have genes coding 
for the HLA DQ2 and/or DQ8 molecules. HLA 
DQ2/DQ8 are present in 95% of all celiac patients and 
their absence can be used to rule out the diagnosis of 
CD in 95% of all cases (8). HLA DQ2-DQ8 are present 
in 30% of Healthy subjects. As such, it does not appear 
to be a significant association between the celiac 
disease HLA markers and NCGS. 
Clinical Diagnosis of NCGS 
Volta et al (19), in a multi-center Italian study of 486 
patients responsive to a gluten-free diet (GFD), 
reported that most patients showed associated 
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gastrointestinal and extra-intestinal symptoms. Bloating 
and abdominal Pain were the most important 
gastrointestinal symptoms (> 80%), whereas more than 
50% of these patients reported diarrhea, 27% 
alternating bowel habits and 24% constipation (19). 
Other symptoms included epigastric pain, nausea, 
aerophagia, gastro-esophageal reflux disease and 
aphtous stomatitis. Tiredness, lack of well-being, 
neuropsychiatric symptoms as headache, anxiety, 
“foggy mind”, arm/leg numbness, depression, muscle 
or joint pain, weight loss, dermatitis, skin rash featured 
prominently among the extraintestinal symptoms of 
NCGS. There was an “overlap” between irritable bowel 
syndrome (IBS) and NCGS with regard to symptoms 
(20). In patients with clinical characteristics compatible 
with Rome III criteria for IBS, particularly in those 
with diarrhea, NCGS is diagnosed in a high percentage 
of cases; (21). Shahbazkhani et al. (22) found a large 
percentage of IBS patients (83%) to be gluten sensitive 
in their trial (72 patients). Also in patients with allergic 
disorders, a high prevalence of NCGS was reported by 
Massari et al. (77 NCGS/262 allergic patients) (23). 
The reported prevalence of NCGS, at this moment, 
varies between 0.6 and 6% (1). Anti-gliadinliadin 
antibodies may be present in about 50% of patients 
with suspected NCGS (24).  Based on Salerno expert 
criteria, the patient may have 1 to 3 main symptoms 
that are quantitatively assessed using a Numerical 
Rating Scale with a score ranging from 1 to 10 (21, 25). 
The double blind placebo controlled gluten challenge (8 
g/day) includes a one-week challenge followed by a 
one-week wash-out of strict GFD and a new crossover 
to the second one-week challenge (25). The vehicle for 
the challenge should contain cooked, homogeneously 
distributed gluten (25).  
A variation of 30% in 1 to 3 main symptoms between 
the gluten and placebo may discriminate positive from 
negative results (25).  The Salerno Criteria (25) is the 
most reliable tool so far for diagnosing NCGS. 
However, it has a limited applicability in clinical 
practice outside the clinical trials. Most of the clinicians 
use an open gluten challenge fashion to ascertain the 
diagnosis of NCGS. An open gluten challenge is the 
most practical way forward, despite reduced diagnostic 
accuracy. Further study would be needed to introduce a 
pragmatic and more practical policy to help clinician to 




Figure 1. A: Linear disposition of T lymphocytes at the base 
of the mucosa CD3 immunohistochenistry 40x; B: Cluster of 
¾ lymphocytes in the superficial epithelium (red circle) CD3 
immunohistochemistry 100x; C: Eosinophils in lamina 
propria H&E 100 x. 
 
The clinical observation in Salerno expert criteria 
includes an administration of a modified version of the 
Gastrointestinal Symptom Rating Scale (GSRS) based 
on reviews of gastrointestinal symptoms and clinical 
symptoms almost largely used to evaluate common 
symptoms of Gastrointestinal Disorders (26). The 
patient identifies 1 to 3 main symptoms that may be 
evaluated using a Numerical Rating Scale (NRS) with a 
score ranging from 1 (mild) to 10 (severe). The 
instruction includes item evaluating also extra intestinal 
symptoms. Elli et al. (27) performed a multicenter 
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double-blind-placebo controlled trial with crossover 
enrolling 134 patients (17 males and 117 females); 98 
of these patients underwent a gluten challenge after 3 
weeks long GFD and 28 of these, all females, reported 
a symptomatic relapse and deterioration of quality of 
life. 
Duodenal Histology of NCGS 
The histologic characteristics of NCGS are still under 
investigation, ranging from reports of apparently 
normal histology to slight increase of T lymphocytes in 
the superficial epithelium of normal villi (28). In a 
recent editorial, Talley and colleagues (29) reported the 
presence of high intraepithelial lymphocytes (IEL) and 
increased duodenal eosinophils in some cases of 
NCGS, but underlined the overlap of these findings in 
patients with functional gastrointestinal disorders (29). 
Villanacci V et al. (30) have reported that patients with 
NCGS might have a normal number of T lymphocytes 
but a peculiar disposition of this cells in small “cluster” 
of ¾ elements in the superficial epithelium and a linear 
disposition in the deeper part of the mucosa together 
with an increased number of eosinophils in lamina 
propria (Villanacci V unpublished data). A slight 
increase of gamma delta T cell receptors in NCGS has 
also been reported by some studies (1). Brottveit et al. 
(31) studied the initial mucosal immunologic events in 
CD and NCGS patients before and after a gluten 
challenge, showed an increase of interferon gamma and 
Heat Shock Protein 27 levels after gluten challenge and 
confirmed the presence of a higher density of 
intraepithelial lymphocytes. Bucci et al. (32) did not 
found any gliadin related immunologic alteration in the 
duodenal mucosa of NCGS patients. In NCGS patients, 
basophil activation was reported to be positive in 66% 
of patients responding to wheat blind challenge and to 
be associated with duodenal intraepithelial 
lymphocytosis and eosinophilic infiltration of the 
duodenum and the colon (33). Sub-microscopic 
changes or duodenal Intraepithelial Lymphocytosis 
may be present in about 50% of NCGS cases under 
definition of Microscopic Enteritis (34).  
 
 
Figure 2. Studies listed in table 1 suggest over 70% of 
patients with irritable bowel syndrome (IBS) respond to 
gluten free diet (GFD) with reoccurring the symptoms on 
gluten challenge (GC). For targeted and effective treatment it 
is essential to recognise and differentiate non-coeliac gluten 
sensitivity from IBS 
 
Open Questions 
The lack of standardized biomarkers remains an 
important challenge in the diagnosis of NCGS. The 
clinical symptoms are not specific and they may be 
confused with other conditions like IBS (1). The 
current algorithm recommends the exclusion of CD and 
Table 1. Gluten free diet effect assessed by double-blind placebo-controlled oral gluten challenge trials in IBS patients (authors 
and reference number first column).  
Authors  No of IBS Study design Am Gluten Outcome 
Cooper et al. 1980 (7) 6 DBPC (20 g/d) Sig Improv 
Biesiekierski et al. 2011 (41) 34 DBPC (16 g/d) Sig Improv 
Carroccio et al. 2012 (34) 276 DBPC (13 g/d) Sig Improv 
Shahbazkhani et al (22) 72 DBPC 52g/day Sig Improv 
Di Sabatino et al. 2015 (38) 61 DBPC (4.375 g/d) Sig Improv 
Zanini et al. 2015 (37) 35 DBPC (10g/d) Sig Improv 
Elli et al. 2016 (27) 98 DBPC (5.6 g/d) Sig Improv 
Barmeyer et al 2016 (40) 35 Observational  90% 
Zanwar et al (39)  60 DBPC   
Abbreviations: Sig Improvement: significant improvement, DBPC: double blind placebo controlled; IBS: irritable bowel syndrome 
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wheat allergy and symptomatic improvement on GFD 
(25).  
Principal remaining questions pertain to what is 
triggering NCGS and why some people suddenly 
become gluten intolerant. The factors implicated in the 
occurrence of NCGS remain largely unknown and it is 
unclear who is susceptible to this condition. It has been 
suggested that dysbiosis following a gastroenteritis 
might count as a risk factor for NCGS (35).   
The future research agenda should explore the genetic 
background, histological characteristic, susceptibility 
and risk factors for NCGS in addition to developing 
reliable biomarkers. It is essential to separate NCGS 
from IBS as IBS is a non-specific condition and IBS 
therapies not only are not effective in NCGS, but also 
these medications and their side effect may impair the 
quality of life of NCGS patients and adversely drain the 
healthcare resources (36-42). See table 1 and figures 1, 
2. 
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